Skip to main content

Table 3 Treatment factors and results of the EA group

From: Can metagenomic next-generation sequencing identify the pathogens responsible for culture-negative prosthetic joint infection?

CaseTsukayama typeSurgical protocolAntibiotic regimenReason for culture-negativeFollow-up (month)Subsequent interventionAntibiotic costs
(Yuan)
IntravenousOral
EA-1IVTwo-stage revisionVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Unknown348587.82
EA-2IVTwo-stage revisionVancomycin
Meropenem
Levofloxacin
Rifampicin
Unknown34I&D39,572.64
EA-3IVTwo-stage revisionVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Unknown3816,837.93
EA-4IVTwo-stage revisionVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Unknown376697.8
EA-5III&DVancomycin
Levofloxacin
Levofloxacin
Rifampicin
Prior use of antibiotics43I&D23,050.38
EA-6III&DVancomycin
Meropenem
Levofloxacin
Rifampicin
Prior use of antibiotics40Suppressive antibiotic therapy30,235.4
EA-7IVOne-stage revisionVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Prior use of antibiotics373236.38
EA-8III&DVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Unknown429051.3
EA-9III&DVancomycin
Meropenem
Levofloxacin
Rifampicin
Prior use of antibiotics4145,297.16
EA-10III&DVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Unknown446583.4
EA-11IVTwo-stage revisionVancomycin
Moxifloxacin
Levofloxacin
Rifampicin
Unknown3813,756.7
EA-12IVTwo-stage revisionVancomycin
Ceftazidime
Levofloxacin
Rifampicin
Prior use of antibiotics41I&D39,113.54